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A new coronavirus SARS-CoV-2 emerged at the start of 2020
with rapid worldwide spread. It is the causative agent of
Coronavirus Disease 2019 (COVID-19). The resulting pan-
demic has been challenging for centres undertaking autolo-
gous and allogeneic haematopoietic stem cell transplants
(HSCT). One of the main risks in HSCT is infection suscep-
tibility, including viral infections, which are often more sev-
ere and life-threatening.1
In response to the COVID-19 pandemic, the National
Institute for Health and Care Excellence (NICE) published
the first version of the COVID-19 rapid guideline for HSCT
(NG164) on 1 April 20202; this was updated on 29 July 2020
in response to the changing context of the pandemic. The
British Society of Blood and Marrow Transplantation and
Cellular Therapy (BSBMTCT) and the European Society for
Blood and Marrow Transplantation (EBMT) also developed
detailed guidance to support transplant centres.3-5
This paper describes the development and update pro-
cesses for NICE NG164, detailing the rationale behind the
recommendations, implementation and the impact of
COVID-19 on HSCT activity in the UK compared with
2019, based on registrations in the BSBMTCT registry. The
full NICE guidance can be obtained from: https://www.nice.
org.uk/guidance/ng164.
Process and methods for guideline
development
NICE NG164 was developed jointly by NICE and NHS Eng-
land and NHS Improvement (NHSE&I) in March 2020. The
main stages of development included scoping, appointing an
independent advisory expert panel, conducting evidence
reviews, drafting recommendations, as well as targeted peer
review through stakeholder consultation. The cross-speciality
independent clinical advisory panel for HSCT included
experts from the BSBMTCT, the NHSE&I Clinical Reference
Group (CRG) for Blood and Marrow Transplantation
(BMT), supported by the NICE guideline development
team.
The clinical review considered how the delivery of HSCT
services should be managed for patients and donors during
the COVID-19 pandemic and how to mitigate risks of
COVID-19, at all stages of HSCT. An initial literature
search was undertaken on 24 March 2020, in the early days
of the pandemic when little information was available on
COVID-19. A targeted approach was taken to identify pub-
lished and preprint guidance and evidence. The recommen-
dations were informed by a combination of evidence and
expert panel consensus. The final guideline scope and
equality impact assessment and the interim process and
methods manual are published on the NICE website.6 An
update of the NICE guideline was published, incorporating
advice based on emerging evidence on the SARS-CoV-2
virus, the epidemiology and clinical impact.7 A surveillance
approach was implemented following publication involving
frequent searches of literature and guidance, and a prag-
matic intelligence gathering approach to identify other
information which could impact on recommendations, such
as changing COVID-19 alert levels and implementation
feedback.
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Communicating with patients and minimising
risk
Patients undergoing HSCT experience significant anxiety and
distress.8 The Shielding Behavioural Survey undertaken by
the Office for National Statistics (ONS) in June 2020 showed
that 35% of people who are clinically extremely vulnerable
reported that their mental health had become slightly worse
(29%) or much worse (6%).9 A survey undertaken by
Anthony Nolan, using the same wording as the ONS survey,
showed that 79/139 (57%) of respondents reported that their
mental health had become slightly worse (57/139, 41%) or
much worse (22/139, 16%) as a result of the coronavirus
pandemic (Anthony Nolan, personal communication).
To support their mental wellbeing, the guideline recom-
mends signposting of patients and families to charities and
support groups. Documented examples include a local trans-
plant teams support telephone line established during the
pandemic by Anthony Nolan.10
NG164 recommends measures to mitigate risks of nosoco-
mial transmission, including telephone or video consultations,
avoiding non-essential clinic visits, coordinating blood tests
and using alternative means of delivering medications. Many
of these measures had been successfully implemented in cen-
tres across the UK.11 Additionally, transplant centre healthcare
workers are advised to follow UK guidance on infection pre-
vention and control which includes the use of personal protec-
tive equipment (PPE) and recommendations on patient
transfers, transport and options for outpatient settings.12
Patients with new symptoms of COVID-19
Patients undergoing HSCT are immunocompromised and
may have atypical presentations of SARS-CoV-2 infection.13
They are also susceptible to other post-transplant complica-
tions which may have similar symptoms to COVID-19,
including neutropenic sepsis or pneumonia caused by other
pathogens. The expert panel was concerned that patients
who feel unwell may be advised to isolate at home, which
means that other types of infection or neutropenic sep-
sis―which is immediately life-threatening―could be
missed. Consequently, the guideline recommends that
patients with new symptoms suggestive of COVID-19 con-
tact their transplant centre rather than the national NHS
emergency telephone number, in order to receive specialist
advice. The guidance also aligns with existing NICE guid-
ance for people with cancer and suspected neutropenic sep-
sis, recommending assessment in secondary or tertiary care
and offering immediate empirical antibiotic therapy (NICE
CG15114).
Patients with symptoms suggestive of COVID-19 require
testing for SARS-CoV-2. Isolation and the use of PPE are
required until the test result is known.15 If a patient tests
positive for SARS-CoV-2, NG164 recommends following UK
guidance on the management of exposed healthcare workers
and patients in hospital settings, which includes information
on testing and isolating patients.15
Transplant recipients pre-transplant
Transplant recipients are susceptible to viral infections, and
evidence shows that respiratory viral infections can increase
transplant-related mortality.1 Recent evidence also suggests
that this is true for HSCT patients who develop a SARS-
CoV-2 infection,16-19 and advice includes social distancing,
regular hand washing and self-isolation for the 14 days prior
to admission. Patients should also be tested for SARS-CoV-2
prior to admission regardless of whether they have symp-
toms, due to the high rate of asymptomatic carriers of the
virus (reviewed in Ref. 20).
If patients have been in close contact with an individual
infected with COVID-19 within the preceding week, deferral
of transplant by three weeks was recommended. This recom-
mendation was in line with EBMT guidance at that time, but
since then the interval has been reduced to ‘a minimum of
14 days’ by the EBMT before the start of any transplant-re-
lated procedures and could be subject to further change.3,5
In patients with high-risk haematological disease progres-
sion, morbidity or mortality who test positive for SARS-
CoV-2, it is recommended that transplant is deferred until
they are asymptomatic and have three negative polymerase
chain reaction (PCR) tests taken at least one week apart,
similar to EBMT guidance which recommends two negative
swabs, a deferral of 14 days from the first negative swab and
a repeated swab prior to the start of conditioning.3 In
patients with lower risk disease it is suggested that their
transplant is delayed by three months. A repeat assessment
of organ function including a chest X-ray, echocardiogram
and pulmonary function tests is recommended as organ
function may have deteriorated due to the SARS-CoV-2
infection.
Transplant donors
Following the initial rapid spread of SARS-CoV-2, the peak
of infection in the general population occurred in mid-April
202021 with COVID-19 deaths peaking soon afterwards. Mea-
sures were required to reduce the risk and to mitigate the
potential interruption to a planned transplant. For example,
transplant centres and donor registries advised donors to fol-
low government guidance on strict social distancing beha-
viour for at least four weeks before donating. Donors were
advised to keep in contact with the harvest centre and to
seek advice if they developed any symptoms suggestive of
COVID-19. Due to the reported asymptomatic carriage of
the virus by individuals, which ranges from 18%–88%
depending upon the population studied,22,23 screening by
throat and nasal swabs for SARS-CoV-2 PCR at least once
prior to donation and ideally on the day of donation was
recommended. Screening on the day of donation was
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intended to provide an audit trail rather than inform the use
of the harvested stem cells. In theory it was possible that a
donor would be asymptomatic but positive for COVID-19
on the day of donation. There have been reports of SARS-
CoV-2 RNA being detected in several organs and in blood;24
however, the presence of the potentially infectious virus in
blood, and hence blood products, in an asymptomatic donor
is remote.25,26 The swab test on the day of donation would
allow tracing in the event that a transplant recipient became
unwell with COVID-19 post-transplant. Similarly, donors
were asked to inform harvest teams if they developed any
COVID-19 symptoms within two weeks of donation.27
A major change in the allogeneic transplant procedure was
a recommendation by some donor registries to cryopreserve
stem cells prior to the start of conditioning for the recipient,
based on BSBMTCT recommendations and expert consen-
sus.3,4,27,28 The intention of this recommendation was to
avoid the possibility that a donor was unable to donate due
to developing COVID-19. Evidence from two retrospective
studies indicated that the use of cryopreserved stem cells in
allogeneic transplantation had no impact on transplant out-
come.29,30 If fresh cells were to be used, it was recommended
that an alternative donor, including for haplo-identical or
cord blood, was identified in case the selected donor was
unable to donate.
Donors who had tested positive for COVID-19, even if
asymptomatic, were required to be deferred for three months
after the resolution of symptoms. This is longer than the per-
iod of 28 days recommended by the EBMT3,5, but with
evidence of long-term medical complications following
COVID-19 the longer period of deferral seemed appropriate.
However, it was recognised that in situations where the clini-
cal urgency of the transplant was high then earlier donation
would be possible with a risk assessment, an asymptomatic
period and repeated negative swabs for SARS-CoV-2 prior to
donation.
Transplant recipients post-transplant
Based on the increased risk of mortality from other respira-
tory viruses31, it was highly probable that transplant recipi-
ents would be at increased risk of mortality from SARS-CoV-
2. Emerging evidence supports this assumption with data
from the EBMT COVID-19 survey reporting the outcome of
confirmed COVID-19 infection in 272 patients, 175 allo-
geneic SCT and 97 autologous SCT. The mortality rate was
30% in allogeneic recipients and 253% in autologous recipi-
ents.17 A smaller report in 25 patients with haematological
malignancies reported a mortality rate of 40% but only seven
HSCT recipients were included in this study.32 The CIBMTR
registry has a cumulative reporting process and by the end of
September 2020 a total of 554 cases of COVID-19 had been
reported, with a mortality rate of 191%.33 As with sub-
groups of patients with haematological malignancies, similar
high mortality rates in HSCT recipients have been
reported.18,19 Strict social distancing behaviour was recom-
mended in line with current guidelines.3,4,12
Supporting staff
Depletion of experienced transplant teams was acknowledged
with staff remaining away from work, either due to symp-
tomatic infection, contact with proven cases, or personal rea-
sons.12 The risk of nosocomial infection from staff was of
great concern34; in the report by Malard, a large number of
infections in patients with haematological malignancies were
thought to have been acquired in hospital.32 It was therefore
important to ensure that transplant programmes could pro-
vide ‘COVID-19 safe’ environments with a key component
being education of staff on the symptoms of COVID-19, reg-
ular symptom checks and routine screening of asymptomatic
staff whenever possible. During the preparation of the guide-
line it was clear that there was uncertainty regarding the per-
iod that an individual may remain potentially infective, with
reports of prolonged positivity by PCR despite resolution of
symptoms.24,35 Return to work recommendations from the
World Health Organization (WHO), Centers for Disease
Control and Prevention (CDC), European Centre for Disease
Prevention and Control (ECDC) and EBMT indicated that
staff should be asymptomatic, fever being the main symptom
to have been resolved, have a minimum time-period since
onset of symptoms and ideally two negative swabs for SARS-
CoV-2.
The approach by the NICE guidelines group was prag-
matic, acknowledging the rapidly changing evidence and lim-
itations of testing.36-40 Rivett et al. reported the results of a
screening programme for asymptomatic staff in a large teach-
ing hospital in the UK,41 indicating that the presence or
absence of symptoms alone would miss individuals still
potentially shedding virus. Similar to the ‘test-based strategy’
of the CDC,42 a recommendation was made for staff to be
asymptomatic for at least seven days plus a negative SARS-
CoV-2 swab PCR test prior to returning to direct contact
with transplant recipients.
The creation of ‘COVID-19 safe’ environments for trans-
plant recipients was based on the provision of regular swab
testing of staff. As of September 2020, PCR testing for SARS-
CoV-2 was limited and routine testing of asymptomatic staff
was not achieved in all sites despite the NICE recommenda-
tion. A BSBMTCT survey of the 53 transplant units in the
UK conducted in September 2020 received 42 responses; of
these only 24 (57%) of centres were offering routine testing
of asymptomatic staff with the majority (83%) using nose
and throat swab tests for SARS-CoV-2 (Bloor et al., BJH
2020 accepted).
Prioritising treatment
Given the uncertainties during the early phase of the COVID
pandemic, there was a need to prioritise HSCT procedures
COVID 19
ª 2020 The Authors. British Journal of Haematology published by British Society for Haematology
and John Wiley & Sons Ltd. British Journal of Haematology, 2021, 192, 467–473
469
depending on risk of disease indication if untreated by
HSCT, and potential risk of severe COVID-19 infection dur-
ing and after HSCT. To inform shared decision-making with
patients, NICE recommended that multidisciplinary teams
(MDTs) consider using transplant outcome predictive tools
such as the haematopoietic cell transplantation-specific
comorbidity index (HCT-CI)43,44 or the refined disease risk
index (DRI),45 but also to be aware of the limitations of
these tools. Prioritising treatment for people with high risk
of haematological disease progression, morbidity or mortality
enabled units to focus on critically urgent, curative HSCT
procedures concentrated in larger units where COVID-19-
minimised pathways could be provided. Close liaison within
local MDTs was recommended to consider suitable alterna-
tive treatments if the risks associated with COVID-19 were
felt to be higher than the risk of continuing with the trans-
plant.
Modifications to usual care
NICE recommended different ways of working within HSCT
programmes, as well as regional (adults) and national (paedi-
atrics) via ‘clusters’ of HSCT centres within operational
delivery networks (ODNs) to provide a ‘safety net’ should
any programmes fail to maintain quality standards and/or
meet demands in activity. ODNs were extended to support
devolved nations. Modifications to haematopoietic stem cell
collection (apheresis and bone marrow harvest) practice and
facilities were also recommended. Engagement between stake-
holders was critical,3,5,27,46,47 along with reporting into the
EBMT registry experience.17
Impact of COVID-19 on HSCT activity in the UK
Table I and Fig 1A,B summarise the autologous and allo-
geneic HSCT activity (adult and paediatric combined) as
reported to the BSBMTCT registry during the period 1 Jan–
31 July in 2019 and 2020. Both autologous and allogeneic
HSCT activity fell in March 2020, reaching a nadir in April
2020, which corresponded with the peak of the COVID-19
crisis in the UK. Autologous HSCT was reduced to a greater
extent than allogeneic HSCT, reaching 164% of the 2019
activity, while allogeneic HSCT fell to 65%.
These data show the total transplant activity in the UK
but there was considerable heterogeneity of the impact
around the country; some small autologous HSCT units
ceased all activity, and some large programmes reduced
autologous HSCT activity but maintained allogeneic activity
close to 2019 levels, while some large programmes reduced
both (BSBMTCT registry data). The impact of the COVID-
19 crisis on individual centres was influenced by several fac-
tors, including local infection rates, staffing levels and risk
assessments. The reduction of transplant activity, particularly
for autologous HSCT, created a large ‘backlog’ of patients
awaiting transplantation, and, by the time of the second wave
of the pandemic, HSCT in the UK was still in recovery phase
as activity had still not reached that of 2019.
Conclusion
The COVID-19 pandemic has posed an exceptional challenge
for the stem cell transplant community which responded
quickly by publishing relevant guidance for the management
of transplant recipients, advice on safe service delivery and
donor issues4, and was updated in response to new evidence
and government advice. The advice and experience from
experts within EBMT was invaluable in formulating these
guidelines.3 The NHS also responded quickly to the complex
issues posed by the pandemic to support patients, NHS
trusts, clinicians and commissioners. The guidelines will
require ongoing review as more clinical evidence emerges
and government advice changes to address further ‘waves’ of
the pandemic, and, ultimately, the challenge of ‘endemic’
COVID-19.
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